OBIM.F Stock Overview
A life-sciences company, engages in the development and commercialization of antimicrobial therapies in Canada and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 3 more risks
Ondine Biomedical Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.12 |
| 52 Week High | UK£0.25 |
| 52 Week Low | UK£0.12 |
| Beta | 0.14 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -52.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| OBIM.F | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0% | 0.007% | -0.06% |
| 1Y | n/a | -1.4% | 20.5% |
Return vs Industry: Insufficient data to determine how OBIM.F performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how OBIM.F performed against the US Market.
Price Volatility
| OBIM.F volatility | |
|---|---|
| OBIM.F Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 8.2% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: OBIM.F's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine OBIM.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | n/a | Carolyn Cross | ondinebio.com |
Ondine Biomedical Inc., a life-sciences company, engages in the development and commercialization of antimicrobial therapies in Canada and internationally. Its product platform is Photodisinfection, a light-based antimicrobial technology that provides destruction of pathogens without causing antibiotic resistance. The company’s lead product is Steriwave, a nasal photodisinfection solutions that destroys bacteria, viruses, and fungi colonizing the nose which leads to healthcare-associated infections.
Ondine Biomedical Inc. Fundamentals Summary
| OBIM.F fundamental statistics | |
|---|---|
| Market cap | US$27.17m |
| Earnings (TTM) | -US$10.53m |
| Revenue (TTM) | US$879.25k |
30.9x
P/S Ratio-2.6x
P/E RatioIs OBIM.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OBIM.F income statement (TTM) | |
|---|---|
| Revenue | CA$1.20m |
| Cost of Revenue | CA$500.00k |
| Gross Profit | CA$703.00k |
| Other Expenses | CA$15.12m |
| Earnings | -CA$14.41m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.052 |
| Gross Margin | 58.44% |
| Net Profit Margin | -1,198.01% |
| Debt/Equity Ratio | 0% |
How did OBIM.F perform over the long term?
See historical performance and comparison